{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:42:04Z","timestamp":1792590124846,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["NIHR300118"],"award-info":[{"award-number":["NIHR300118"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Perinatol"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>We examined whether erythropoietin monotherapy improves neurodevelopmental outcomes in near-term and term infants with neonatal encephalopathy (NE) in low-middle income countries (LMICs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched Pubmed, Embase, and Web of Science databases to identify studies that used erythropoietin (1500\u201312,500 units\/kg\/dose) or a derivative to treat NE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Five studies, with a total of 348 infants in LMICs, were retrieved. However, only three of the five studies met the primary outcome of death or neuro-disability at 18 months of age or later. Erythropoietin reduced the risk of death (during the neonatal period and at follow-up) or neuro-disability at 18 months or later (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Death or neuro-disability occurred in 27.6% of the erythropoietin group and 49.7% of the comparison group (risk ratio 0.56 (95% CI: 0.42\u20130.75)).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The pooled data suggest that erythropoietin monotherapy may improve outcomes after NE in LMICs where therapeutic hypothermia is not available.<\/jats:p><\/jats:sec>","DOI":"10.1038\/s41372-021-01132-4","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T12:02:46Z","timestamp":1624708966000},"page":"2134-2140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Erythropoietin monotherapy for neuroprotection after neonatal encephalopathy in low-to-middle income countries: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"41","author":[{"given":"Phoebe","family":"Ivain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6034-7976","authenticated-orcid":false,"given":"Paolo","family":"Montaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamir","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramyia","family":"Elagovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Burgod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Moreno","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuti","family":"Pant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhin","family":"Thayyil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,26]]},"reference":[{"key":"1132_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.earlhumdev.2010.05.010","volume":"86","author":"JJ Kurinczuk","year":"2010","unstructured":"Kurinczuk JJ, White-Koning M, Badawi N. Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy. Early Hum Dev. 2010;86:329\u201338.","journal-title":"Early Hum Dev"},{"key":"1132_CR2","doi-asserted-by":"crossref","unstructured":"Oorschot DE, Sizemore RJ, Amer AR. Treatment of neonatal hypoxic-ischemic encephalopathy with erythropoietin alone, and erythropoietin combined with hypothermia: history, current status, and future research. Int J Mol Sci. 2020;21.","DOI":"10.3390\/ijms21041487"},{"key":"1132_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/pr.2013.206","volume":"74","author":"AC Lee","year":"2013","unstructured":"Lee AC, Kozuki N, Blencowe H, Vos T, Bahalim A, Darmstadt GL, et al. Intrapartum-related neonatal encephalopathy incidence and impairment at regional and global levels for 2010 with trends from 1990. Pediatr Res. 2013;74:50\u201372.","journal-title":"Pediatr Res"},{"key":"1132_CR4","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S0140-6736(05)71048-5","volume":"365","author":"JE Lawn","year":"2005","unstructured":"Lawn JE, Cousens S, Zupan J. Lancet neonatal survival steering T. 4 million neonatal deaths: when? Where? Why? Lancet. 2005;365:891\u2013900.","journal-title":"Lancet"},{"key":"1132_CR5","first-page":"CD003311","volume":"1","author":"SE Jacobs","year":"2013","unstructured":"Jacobs SE, Berg M, Hunt R, Tarnow-Mordi WO, Inder TE, Davis PG. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst Rev. 2013;1:CD003311.","journal-title":"Cochrane Database Syst Rev"},{"key":"1132_CR6","doi-asserted-by":"publisher","first-page":"e58834","DOI":"10.1371\/journal.pone.0058834","volume":"8","author":"SS Pauliah","year":"2013","unstructured":"Pauliah SS, Shankaran S, Wade A, Cady EB, Thayyil S. Therapeutic hypothermia for neonatal encephalopathy in low- and middle-income countries: a systematic review and meta-analysis. PLoS ONE. 2013;8:e58834.","journal-title":"PLoS ONE"},{"key":"1132_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-2165-3","volume":"18","author":"S Thayyil","year":"2017","unstructured":"Thayyil S, Oliveira V, Lally PJ, Swamy R, Bassett P, Chandrasekaran M, et al. Hypothermia for encephalopathy in low and middle-income countries (HELIX): study protocol for a randomised controlled trial. Trials. 2017;18:432.","journal-title":"Trials"},{"key":"1132_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.siny.2014.10.004","volume":"20","author":"P Montaldo","year":"2015","unstructured":"Montaldo P, Pauliah SS, Lally PJ, Olson L, Thayyil S. Cooling in a low-resource environment: lost in translation. Semin Fetal Neonatal Med. 2015;20:72\u20139.","journal-title":"Semin Fetal Neonatal Med"},{"key":"1132_CR9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.clp.2015.04.004","volume":"42","author":"SE Juul","year":"2015","unstructured":"Juul SE, Pet GC. Erythropoietin and neonatal neuroprotection. Clin Perinatol. 2015;42:469\u201381.","journal-title":"Clin Perinatol"},{"key":"1132_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1542\/peds.2012-0498","volume":"130","author":"YW Wu","year":"2012","unstructured":"Wu YW, Bauer LA, Ballard RA, Ferriero DM, Glidden DV, Mayock DE, et al. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics. 2012;130:683\u201391.","journal-title":"Pediatrics"},{"key":"1132_CR11","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1161\/STROKEAHA.109.570325","volume":"41","author":"M Iwai","year":"2010","unstructured":"Iwai M, Stetler RA, Xing J, Hu X, Gao Y, Zhang W, et al. Enhanced oligodendrogenesis and recovery of neurological function by erythropoietin after neonatal hypoxic\/ischemic brain injury. Stroke. 2010;41:1032\u20137.","journal-title":"Stroke"},{"key":"1132_CR12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1203\/pdr.0b013e3180332cec","volume":"61","author":"BA Kellert","year":"2007","unstructured":"Kellert BA, McPherson RJ, Juul SE. A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal rats. Pediatr Res. 2007;61:451\u20135.","journal-title":"Pediatr Res"},{"key":"1132_CR13","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1161\/STROKEAHA.107.483008","volume":"38","author":"M Iwai","year":"2007","unstructured":"Iwai M, Cao G, Yin W, Stetler RA, Liu J, Chen J. Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia\/ischemia in rats. Stroke. 2007;38:2795\u2013803.","journal-title":"Stroke"},{"key":"1132_CR14","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1161\/01.STR.0000132196.49028.a4","volume":"35","author":"L Wang","year":"2004","unstructured":"Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke. 2004;35:1732\u20137.","journal-title":"Stroke"},{"key":"1132_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1159\/000486820","volume":"113","author":"SE Juul","year":"2018","unstructured":"Juul SE, Comstock BA, Heagerty PJ, Mayock DE, Goodman AM, Hauge S, et al. High-dose erythropoietin for asphyxia and encephalopathy (HEAL): a randomized controlled trial-background, aims, and study protocol. Neonatology. 2018;113:331\u20138.","journal-title":"Neonatology"},{"key":"1132_CR16","first-page":"ED000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019;10:ED000142.","journal-title":"Cochrane Database Syst Rev"},{"key":"1132_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/ped.12121","volume":"55","author":"A Avasiloaiei","year":"2013","unstructured":"Avasiloaiei A, Dimitriu C, Moscalu M, Paduraru L, Stamatin M. High-dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatr Int. 2013;55:589\u201393.","journal-title":"Pediatr Int"},{"key":"1132_CR18","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3109\/14767058.2013.855894","volume":"27","author":"MS El Shimi","year":"2014","unstructured":"El Shimi MS, Awad HA, Hassanein SM, Gad GI, Imam SS, Shaaban HA, et al. Single dose recombinant erythropoietin versus moderate hypothermia for neonatal hypoxic ischemic encephalopathy in low resource settings. J Matern Fetal Neonatal Med. 2014;27:1295\u2013300.","journal-title":"J Matern Fetal Neonatal Med"},{"key":"1132_CR19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/jp.2017.17","volume":"37","author":"RR Malla","year":"2017","unstructured":"Malla RR, Asimi R, Teli MA, Shaheen F, Bhat MA. Erythropoietin monotherapy in perinatal asphyxia with moderate to severe encephalopathy: a randomized placebo-controlled trial. J Perinatol. 2017;37:596\u2013601.","journal-title":"J Perinatol"},{"key":"1132_CR20","doi-asserted-by":"publisher","first-page":"e1135","DOI":"10.1542\/peds.2009-2268","volume":"125","author":"H Elmahdy","year":"2010","unstructured":"Elmahdy H, El-Mashad AR, El-Bahrawy H, El-Gohary T, El-Barbary A, Aly H. Human recombinant erythropoietin in asphyxia neonatorum: pilot trial. Pediatrics. 2010;125:e1135\u201342.","journal-title":"Pediatrics"},{"key":"1132_CR21","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1542\/peds.2008-3553","volume":"124","author":"C Zhu","year":"2009","unstructured":"Zhu C, Kang W, Xu F, Cheng X, Zhang Z, Jia L, et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics. 2009;124:e218\u201326.","journal-title":"Pediatrics"},{"key":"1132_CR22","doi-asserted-by":"crossref","unstructured":"Wu YW, Mathur AM, Chang T, McKinstry RC, Mulkey SB, Mayock DE, et al. High-dose erythropoietin and hypothermia for hypoxic-ischemic encephalopathy: a phase II trial. Pediatrics. 2016;137.","DOI":"10.1542\/peds.2016-0191"},{"key":"1132_CR23","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.pediatrneurol.2014.08.010","volume":"51","author":"EE Rogers","year":"2014","unstructured":"Rogers EE, Bonifacio SL, Glass HC, Juul SE, Chang T, Mayock DE, et al. Erythropoietin and hypothermia for hypoxic-ischemic encephalopathy. Pediatr Neurol. 2014;51:657\u201362.","journal-title":"Pediatr Neurol"},{"key":"1132_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/pr.2015.101","volume":"78","author":"MC Baserga","year":"2015","unstructured":"Baserga MC, Beachy JC, Roberts JK, Ward RM, DiGeronimo RJ, Walsh WF, et al. Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. Pediatr Res. 2015;78:315\u201322.","journal-title":"Pediatr Res"},{"key":"1132_CR25","first-page":"855","volume":"13","author":"YJ Wang","year":"2011","unstructured":"Wang YJ, Pan KL, Zhao XL, Qiang H, Cheng SQ. Therapeutic effects of erythropoietin on hypoxic-ischemic encephalopathy in neonates. Zhongguo Dang Dai Er Ke Za Zhi. 2011;13:855\u20138.","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"1132_CR26","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.4103\/1673-5374.217338","volume":"12","author":"HY Lv","year":"2017","unstructured":"Lv HY, Wu SJ, Wang QL, Yang LH, Ren PS, Qiao BJ, et al. Effect of erythropoietin combined with hypothermia on serum tau protein levels and neurodevelopmental outcome in neonates with hypoxic-ischemic encephalopathy. Neural Regen Res. 2017;12:1655\u201363.","journal-title":"Neural Regen Res"},{"key":"1132_CR27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4103\/2249-4847.167413","volume":"4","author":"IT Valera","year":"2015","unstructured":"Valera IT, V\u00e1zquez MDC, Gonz\u00e1lez MDR, Jaraba MP, Ben\u00edtez MVR, de la C\u00e1mara Mora\u00f1o C, et al. Erythropoietin with hypothermia improves outcomes in neonatal hypoxic ischemic encephalopathy. J Clin Neonatol. 2015;4:244\u20139.","journal-title":"J Clin Neonatol"},{"key":"1132_CR28","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3389\/fphar.2019.01221","volume":"10","author":"CYZ Lee","year":"2019","unstructured":"Lee CYZ, Chakranon P, Lee SWH. Comparative efficacy and safety of neuroprotective therapies for neonates with hypoxic ischemic encephalopathy: a network meta-analysis. Front Pharmacol. 2019;10:1221.","journal-title":"Front Pharmacol"},{"key":"1132_CR29","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1515\/jpm-2018-0360","volume":"47","author":"A Razak","year":"2019","unstructured":"Razak A, Hussain A. Erythropoietin in perinatal hypoxic-ischemic encephalopathy: a systematic review and meta-analysis. J Perinat Med. 2019;47:478\u201389.","journal-title":"J Perinat Med"},{"key":"1132_CR30","doi-asserted-by":"publisher","first-page":"e000245","DOI":"10.1136\/bmjpo-2017-000245","volume":"2","author":"V Oliveira","year":"2018","unstructured":"Oliveira V, Kumutha JR, N E, Somanna J, Benkappa N, Bandya P, et al. Hypothermia for encephalopathy in low-income and middle-income countries: feasibility of whole-body cooling using a low-cost servo-controlled device. BMJ Paediatr Open. 2018;2:e000245.","journal-title":"BMJ Paediatr Open"},{"key":"1132_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1159\/000047097","volume":"79","author":"C Dame","year":"2001","unstructured":"Dame C, Juul SE, Christensen RD. The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential. Biol Neonate. 2001;79:228\u201335.","journal-title":"Biol Neonate"},{"key":"1132_CR32","doi-asserted-by":"publisher","first-page":"17982","DOI":"10.1523\/JNEUROSCI.2250-11.2011","volume":"31","author":"G Rathnasamy","year":"2011","unstructured":"Rathnasamy G, Ling EA, Kaur C. Iron and iron regulatory proteins in amoeboid microglial cells are linked to oligodendrocyte death in hypoxic neonatal rat periventricular white matter through production of proinflammatory cytokines and reactive oxygen\/nitrogen species. J Neurosci. 2011;31:17982\u201395.","journal-title":"J Neurosci"},{"key":"1132_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000080490","volume":"87","author":"A Kumral","year":"2005","unstructured":"Kumral A, Gonenc S, Acikgoz O, Sonmez A, Genc K, Yilmaz O, et al. Erythropoietin increases glutathione peroxidase enzyme activity and decreases lipid peroxidation levels in hypoxic-ischemic brain injury in neonatal rats. Biol Neonate. 2005;87:15\u20138.","journal-title":"Biol Neonate"},{"key":"1132_CR34","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1073\/pnas.95.8.4635","volume":"95","author":"M Sakanaka","year":"1998","unstructured":"Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA. 1998;95:4635\u201340.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1132_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/ana.24677","volume":"80","author":"J Song","year":"2016","unstructured":"Song J, Sun H, Xu F, Kang W, Gao L, Guo J, et al. Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Ann Neurol. 2016;80:24\u201334.","journal-title":"Ann Neurol"},{"key":"1132_CR36","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1542\/peds.2013-4307","volume":"133","author":"RK Ohls","year":"2014","unstructured":"Ohls RK, Kamath-Rayne BD, Christensen RD, Wiedmeier SE, Rosenberg A, Fuller J, et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics. 2014;133:1023\u201330.","journal-title":"Pediatrics"}],"container-title":["Journal of Perinatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41372-021-01132-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41372-021-01132-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41372-021-01132-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T10:14:55Z","timestamp":1699179295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41372-021-01132-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,26]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1132"],"URL":"https:\/\/doi.org\/10.1038\/s41372-021-01132-4","relation":{},"ISSN":["0743-8346","1476-5543"],"issn-type":[{"value":"0743-8346","type":"print"},{"value":"1476-5543","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,26]]},"assertion":[{"value":"4 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted ethically according to the World Medical Association Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of ethics"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}